iZafe Group AB Series B (IZAFE-B) - Net Assets
Based on the latest financial reports, iZafe Group AB Series B (IZAFE-B) has net assets worth Skr16.49 Million SEK (≈ $1.77 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr40.20 Million ≈ $4.33 Million USD) and total liabilities (Skr23.71 Million ≈ $2.55 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IZAFE-B asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr16.49 Million |
| % of Total Assets | 41.02% |
| Annual Growth Rate | 6.43% |
| 5-Year Change | -66.98% |
| 10-Year Change | 11.51% |
| Growth Volatility | 152.28 |
iZafe Group AB Series B - Net Assets Trend (2010–2024)
This chart illustrates how iZafe Group AB Series B's net assets have evolved over time, based on quarterly financial data. Also explore iZafe Group AB Series B total assets for the complete picture of this company's asset base.
Annual Net Assets for iZafe Group AB Series B (2010–2024)
The table below shows the annual net assets of iZafe Group AB Series B from 2010 to 2024. For live valuation and market cap data, see IZAFE-B company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr9.73 Million ≈ $1.05 Million |
-61.63% |
| 2023-12-31 | Skr25.35 Million ≈ $2.73 Million |
-34.93% |
| 2022-12-31 | Skr38.96 Million ≈ $4.19 Million |
-4.35% |
| 2021-12-31 | Skr40.73 Million ≈ $4.38 Million |
+38.27% |
| 2020-12-31 | Skr29.46 Million ≈ $3.17 Million |
-20.15% |
| 2019-12-31 | Skr36.89 Million ≈ $3.97 Million |
+264.66% |
| 2018-12-31 | Skr10.12 Million ≈ $1.09 Million |
-9.56% |
| 2017-12-31 | Skr11.19 Million ≈ $1.20 Million |
+106.52% |
| 2016-12-31 | Skr5.42 Million ≈ $582.96K |
-37.91% |
| 2015-12-31 | Skr8.72 Million ≈ $938.85K |
-3.52% |
| 2014-12-31 | Skr9.04 Million ≈ $973.08K |
-22.64% |
| 2013-12-31 | Skr11.69 Million ≈ $1.26 Million |
-38.21% |
| 2012-12-31 | Skr18.92 Million ≈ $2.04 Million |
+513.75% |
| 2011-12-31 | Skr3.08 Million ≈ $331.69K |
-24.15% |
| 2010-12-31 | Skr4.06 Million ≈ $437.33K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to iZafe Group AB Series B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16561977900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr55.12 Million | 566.58% |
| Other Components | Skr130.87 Million | 1345.26% |
| Total Equity | Skr9.73 Million | 100.00% |
iZafe Group AB Series B Competitors by Market Cap
The table below lists competitors of iZafe Group AB Series B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CONSENSUS AS.MGM.B SK 5-
F:5XI
|
$14.84 Million |
|
iRobot Corporation
NASDAQ:IRBT
|
$14.84 Million |
|
HPMT Holdings Bhd
KLSE:5291
|
$14.85 Million |
|
SSR Inc
KQ:275630
|
$14.85 Million |
|
Aberforth Smaller Companies Trust PLC
LSE:ASL
|
$14.83 Million |
|
Georgia Capital PLC
LSE:CGEO
|
$14.82 Million |
|
SSP Group PLC
LSE:SSPG
|
$14.82 Million |
|
Copaur Minerals Inc
V:CPAU
|
$14.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in iZafe Group AB Series B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 25,353,000 to 9,728,000, a change of -15,625,000 (-61.6%).
- Net loss of 20,509,000 reduced equity.
- Share repurchases of 4,884,000 reduced equity.
- New share issuances of 88,000 increased equity.
- Other factors increased equity by 9,680,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-20.51 Million | -210.82% |
| Share Repurchases | Skr4.88 Million | -50.21% |
| Share Issuances | Skr88.00K | +0.9% |
| Other Changes | Skr9.68 Million | +99.51% |
| Total Change | Skr- | -61.63% |
Book Value vs Market Value Analysis
This analysis compares iZafe Group AB Series B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.71x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.52x to 10.71x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | Skr0.73 | Skr0.38 | x |
| 2011-12-31 | Skr0.46 | Skr0.38 | x |
| 2012-12-31 | Skr2.36 | Skr0.38 | x |
| 2013-12-31 | Skr1.42 | Skr0.38 | x |
| 2014-12-31 | Skr1.10 | Skr0.38 | x |
| 2015-12-31 | Skr0.93 | Skr0.38 | x |
| 2016-12-31 | Skr0.47 | Skr0.38 | x |
| 2017-12-31 | Skr0.92 | Skr0.38 | x |
| 2018-12-31 | Skr0.47 | Skr0.38 | x |
| 2019-12-31 | Skr1.72 | Skr0.38 | x |
| 2020-12-31 | Skr0.84 | Skr0.38 | x |
| 2021-12-31 | Skr0.88 | Skr0.38 | x |
| 2022-12-31 | Skr0.49 | Skr0.38 | x |
| 2023-12-31 | Skr0.11 | Skr0.38 | x |
| 2024-12-31 | Skr0.04 | Skr0.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently iZafe Group AB Series B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -210.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -257.85%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 2.49x
- Recent ROE (-210.82%) is below the historical average (-87.22%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -145.36% | -157526.53% | 0.00x | 1.20x | Skr-6.31 Million |
| 2011 | -160.33% | -18704.64% | 0.01x | 1.15x | Skr-5.25 Million |
| 2012 | -15.42% | -7462.56% | 0.00x | 1.27x | Skr-4.81 Million |
| 2013 | -61.85% | -126867.08% | 0.00x | 1.46x | Skr-8.40 Million |
| 2014 | -35.07% | 0.00% | 0.00x | 1.67x | Skr-4.08 Million |
| 2015 | -29.76% | 0.00% | 0.00x | 1.42x | Skr-3.47 Million |
| 2016 | -117.33% | 0.00% | 0.00x | 1.49x | Skr-6.90 Million |
| 2017 | -38.16% | -2754.19% | 0.01x | 1.23x | Skr-5.39 Million |
| 2018 | -111.81% | -149.41% | 0.17x | 4.31x | Skr-12.32 Million |
| 2019 | -62.66% | -161.33% | 0.20x | 1.94x | Skr-26.81 Million |
| 2020 | -43.30% | -143.24% | 0.25x | 1.19x | Skr-15.70 Million |
| 2021 | -89.06% | -8207.01% | 0.01x | 1.19x | Skr-40.35 Million |
| 2022 | -60.38% | -3227.16% | 0.01x | 1.30x | Skr-27.42 Million |
| 2023 | -126.91% | -1765.92% | 0.05x | 1.37x | Skr-34.71 Million |
| 2024 | -210.82% | -257.85% | 0.33x | 2.49x | Skr-21.48 Million |
Industry Comparison
This section compares iZafe Group AB Series B's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $289,222,444
- Average return on equity (ROE) among peers: -42.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| iZafe Group AB Series B (IZAFE-B) | Skr16.49 Million | -145.36% | 1.44x | $14.83 Million |
| ADDvise Group AB A (ADDV-A) | $3.30 Million | 33.40% | 2.57x | $4.23 Million |
| ADDvise Group B (ADDV-B) | $835.00 Million | 10.78% | 3.13x | $108.58 Million |
| AddLife AB (publ) (ALIF-B) | $346.60 Million | 22.45% | 2.68x | $1.80 Billion |
| Biotage AB (BIOT) | $990.04 Million | 17.68% | 0.45x | $1.23 Billion |
| Bonesupport Holding AB (BONEX) | $34.30 Million | -321.22% | 4.50x | $1.56 Billion |
| Dynavox Group (DYVOX) | $139.50 Million | 21.36% | 7.22x | $930.88 Million |
| Ortivus AB ser. A (ORTI-A) | $22.41 Million | -97.60% | 2.16x | $322.08K |
| Ortivus AB ser. B (ORTI-B) | $224.47 Million | 5.79% | 0.15x | $14.04 Million |
| S2Medical AB (S2M) | $7.38 Million | -72.91% | 0.51x | $611.88K |
About iZafe Group AB Series B
iZafe Group AB (publ), a medical technology company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home. The company provides Dosell, an automated medication dispenser that handles medication pouches, smart pillboxes, facilitates and enables independent medication, and reminds and alerts in the scheduled doses. It also o… Read more